Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Simcha Raises $25 Million from China Investors for Novel Immunotherapies

publication date: Jun 25, 2020

Simcha Therapeutics, a novel biotech using "directed evolution" to develop immunotherapies based on improved cytokines, raised $25 million in a Series A financing from two China investors -- WuXi AppTec Corporate Venture Fund and Sequoia Capital China -- along with Connecticut Innovations. Simcha is based in New Haven, Connecticut. The company's lead program is based on a customized variant of interleukin-18 (IL-18), a cytokine designed to have more potent antitumor effects than its natural version. More details.....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020